Skip to main content

Table 1 Baseline characteristics of study participants by incident overall cancer

From: C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis

  Overall (N=420,964) No cancer (N=385,985) Incident cancer (N=34,979)
CRP at baseline,(mg/L) 2.4 ± 3.3 2.4 ± 3.3 2.7 ± 3.6
Age at baseline,(years) 56.2 ± 8.1 55.9 ± 8.1 60.2 ± 6.8
Male,n(%) 197,223 (46.9) 178,749 (46.3) 18,474 (52.8)
Ethnic,n(%)
 White 395,650 (94.0) 361,760 (93.7) 33,890 (96.9)
 Asian 9994 (2.4) 9632 (2.5) 362 (1.0)
 African 6829 (1.6) 6557 (1.7) 272 (0.8)
 Mixed background 2551 (0.6) 2427 (0.6) 124 (0.4)
 Unknown 5940 (1.4) 5609 (1.5) 331 (0.9)
Education,n(%)
 No degree 278,328 (66.1) 254,225 (65.9) 24,103 (68.9)
 Degree 137,610 (32.7) 127,166 (33.0) 10,444 (29.9)
 Unknown 5026 (1.2) 4594 (1.1) 432 (1.2)
Townsend deprivation index −1.3 ± 3.1 −1.3 ± 3.1 −1.5 ± 3.0
Standing height, (cm) 168.6 ± 9.3 168.6 ± 9.3 169.3 ± 9.1
BMI, (kg/m2) 27.4 ± 4.8 27.4 ± 4.8 27.6 ± 4.7
Smoking status,n(%)
 Never 230,940 (54.9) 213,858 (55.4) 17,082 (48.8)
 Previous 143,521 (34.1) 129,772 (33.6) 13,749 (39.3)
 Current 44,385 (10.5) 40,431 (10.5) 3954 (11.3)
 Unknown 2118 (0.5) 1924 (0.5) 194 (0.6)
Alcohol use,n(%)
 Never 18,583 (4.4) 17,311 (4.5) 1272 (3.6)
 Previous 14,892 (3.5) 13,547 (3.5) 1345 (3.9)
 Current 386,411 (91.8) 354,112 (91.7) 32,299 (92.3)
 Unknown 1078 (0.3) 1015 (0.3) 63 (0.2)
Physical activity (MET/week),n(%)
 <600 63,447 (15.0) 58,199 (15.1) 5248 (15.0)
 600–3000 252,403 (60.0) 231,494 (60.0) 20,909 (59.8)
 ≥3000 105,114 (25.0) 96,292 (24.9) 8822 (25.2)
Having family cancer history,n(%) 145,198 (34.5) 131,509 (34.1) 13,689 (39.1)
Menopausal,n(%)a
 No 55,655 (24.9) 53,240 (25.7) 2,415 (14.6)
 Yes 133,190 (59.5) 121,674 (58.7) 11,516 (69.8)
 Not sure 34,209 (15.3) 31,665 (15.3) 2544 (15.4)
 Unknown 687 (0.3) 657 (0.3) 30 (0.2)
Oral contraceptive use,n(%)a
 Never 41,599 (18.6) 38,025 (18.4) 3574 (21.7)
 Ever 181,103 (80.9) 168,223 (81.2) 12,880 (78.0)
 Unknown 1039 (0.5) 988 (0.5) 51 (0.3)
Hormone replacement therapy,n(%)a
 Never 138,909 (62.1) 130,148 (62.8) 8761 (53.1)
 Ever 83,657 (37.4) 75,983 (36.7) 7674 (46.5)
 Unknown 1175 (0.5) 1105 (0.5) 70 (0.4)
Assessment center,n(%)
 East Midlands 28,471 (6.8) 26,106 (6.8) 2365 (6.8)
 London 58,162 (13.8) 54,306 (14.1) 3856 (11.0)
 North Eastern England 49,043 (11.7) 44,883 (11.6) 4160 (11.9)
 North West England 88,420 (21.0) 80,906 (21.0) 7514 (21.5)
 Scotland 55,745 (13.2) 50,767 (13.2) 4978 (14.2)
 South East England 12,216 (2.9) 10,874 (2.8) 1342 (3.8)
 South west England 36,372 (8.6) 33,252 (8.6) 3120 (8.9)
 Wales 17,998 (4.3) 16,483 (4.3) 1515 (4.3)
 West Midlands England 37,451 (8.9) 34,445 (8.9) 3006 (8.6)
 Yorkshire and the Humber 37,086 (8.8) 33,963 (8.8) 3123 (8.9)
  1. aAnalysis was only conducted among women
  2. Data are presented as mean ± standard deviation for continuous variables and n (%) for categorical variables